Friday December 1

Agenda Day 2

Panel discussion

Precision oncology needs data sharing: Integrating genomic and clinical data to advance patient care and understanding patient outcomes

  • Does decoding the genes of patients’ cancer help to accelerate the pace of discovery?
  • Is more sequencing, across large populations worthwhile?
  • How to combine all these data into one searchable pool?
  • How will this translate to better and more personalized vaccines or treatments for patients?
  • The paradigm of bringing multiple cancer centers together, connecting academics with industry and how to data share
  • The type of data sharing necessary to learn from the experience of patients that go through cancer immunotherapy
Prof Bali Pulendran

How to effectively manipulate the microbiome to improve efficacy of vaccines and immunotherapy

  • Understanding the microbiome and its interaction with the immune system
  • What evidence is there that one can change the other?
  • Potential opportunities and current challenges in harnessing this knowledge into better treatments
Dr Kara Bortone

Discussion: Driving innovation – Helping biotech’s to succeed from inception to expansion

  • What models can be used to support innovation?
  • What criteria do we look for in choosing biotech’s to work with?
  • How to be successful; programs and strategies to grow your company – how does this apply to vaccines and immunotherapy?

Morning Networking Break


Interactive Roundtables

Choose one of our roundtables for these interactive discussions with like-minded peers tackling the same challenges in:

Common logistics challenges that can delay clinical trials

Fuelling innovation through strategic investments in immunotherapy

In vivo evaluation of biomarkers and immune correlates of vaccine-induced protection

Microbiome biomarkers for cancer immunotherapy: promise and challenges

Overcoming clinical challenges that occur with combining different immuno-oncology approaches

Quality assurance and quality compliance in the development of personalised cancer vaccines


Networking Lunch & Poster Session

Vaccine Technology Platforms & Delivery

Clinical Advancements in Cancer and Autoimmune Diseases

Infectious Diseases

Developing vaccines for viral infections: Addressing HIV and Zika vaccine development

  • Results of Ph1b study for HIV vaccine
  • Moving into Ph11a proof of concept studies
  • Results of Zika pre-clinical studies
  • Preparing for Zika first in human trials
  • Has interest in Zika diminished? Impact on vaccine development

Development of novel, personalized neoantigen immunotherapies

  • Using real time next-generation sequencing and bioinformatics approaches to identify and catalogue neoepitopes for each patient
  • How algorithms have increased the accuracy of identifying neoepitopes from 1% - 40%
  • Manufacture and delivery of personalized cancer vaccines either alone or in combination with other therapeutics
Infectious Diseases

Development of a correlate of protection for a live oral cholera vaccine

  • Review of the immune response to cholera
  • Protective efficacy in a human challenge model
  • Establishment of a correlate for use in pre-licensure studies
  • Extension of this approach for post-approval studies

Optimizing the therapeutic benefit of PD-1 blockade and broadening the potential of immunotherapy

  • The past, present and future of anti-PD-1 therapies
  • Where are we currently with Keytruda monotherapy and biomarkers
  • Updates on our combination strategy and trials with Keytruda and other novel agents
Infectious Diseases

The use of next generation self-amplifying RNA platform systems for vaccine development

  • Why self-amplifying RNA systems?
  • Engineering beneficial attributes into RNA systems
  • In vitro analysis of engineered attributes
  • In vivo analysis of engineered attributes
  • Impact of engineered attributes on immunogenicity

Progress of chimeric antigen receptor (CAR) T-cells as an immuno-oncology treatment

  • Preliminary clinical outcomes of FIM clinical trial of CAR-GPC3 T cells in patients with advanced hepatocellular carcinoma
  • Bottlenecks in tech transfer for CAR-GPC3 T cells cross board manufacturing
  • Regulatory considerations when planning CAR-T clinical trials in China vs in US

Networking Break

Infectious Diseases

Electroporation mediated DNA immunization: Clinical progress and technology development

  • Review of clinical experience with electroporation based intradermal and intramuscular DNA vaccination
  • Development of electroporation device technology to support the development & deployment of novel DNA vaccine candidates
  • Adaptation of electroporation for delivery of DNA encoding monoclonal antibodies

Combining innate cellular therapy and adaptive immune therapy approaches for treatment of recurrent cancer

  • Rationale for combination of adenoviral vaccine with “superkine” IL-15 agonist
  • Partnering with NK cell therapy – mechanisms of action
  • Study design and initial safety
  • Early response data
Infectious Diseases

Immune profiling of T cell responses correlating with pertussis vaccine efficacy

  • Introduction of a whole cell pertussis vaccine in the 1950s led to dramatic reduction in morbidity
  • Whole pertussis inactivated vaccine was associated with significant side effects, replaced in 1997 with acellular version
  • Resurgence of pertussis in teenagers – age of people affected correlates with time when vaccine switched from whole cell vaccine to acellular vaccine occurred
  • Discussion of changes that have been identified in in immune profile between old vaccine and new

Beyond PD1s – Using a tumours composition to activate an immune response through STING pathway

  • Mode of action
  • Planned and ongoing clinical studies
  • Combination with vaccines
  • The importance of STING activation in priming patient’s tumours to respond to checkpoint inhibition
Infectious Diseases

Chair’s Closing Remarks & End of Congress


Chair’s Closing Remarks & End of Congress

last published: 22/Nov/17 13:05 GMT